Firm has requested that an ANDA suitability petition filed by Central Pharmaceuticals for a 15 mg b.i.d. version of cyclobenzaprine be denied on the ground that Merck's data establish the drug's safety and efficacy only in a 10 mg t.i.d. regimen.
You may also be interested in...
Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.
CDRH director Jeff Shuren says the US agency’s device center has been tallying up lessons learned from the COVID-19 pandemic.